BCRX
BioCryst Pharmaceuticals Inc
NASDAQ: BCRX · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$8.99
+1.47% today
Updated 2026-04-29
Market cap
$2.28B
P/E ratio
7.43
P/S ratio
2.61x
EPS (TTM)
$1.21
Dividend yield
—
52W range
$6 – $11
Volume
5.5M
BioCryst Pharmaceuticals Inc (BCRX) Financial statements
SEC filings — annual and quarterly data.
Profit margin
30.20%
Operating margin
65.60%
ROE
-1,925.00%
ROA
43.20%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | $6.21M | $-43.62M | 100.00% | -756.28% | -702.16% |
| 2007 | $71.24M | $-29.06M | 100.00% | -45.31% | -40.79% |
| 2008 | $56.56M | $-24.73M | 100.00% | -48.03% | -43.73% |
| 2009 | $74.59M | $-13.45M | 93.91% | -18.42% | -18.03% |
| 2010 | $63.50M | $-32.73M | 99.86% | -52.34% | -51.55% |
| 2011 | $19.64M | $-56.95M | 100.00% | -252.44% | -289.91% |
| 2012 | $26.29M | $-39.08M | 99.50% | -128.89% | -148.64% |
| 2013 | $17.33M | $-30.11M | 99.43% | -177.24% | -173.72% |
| 2014 | $13.61M | $-45.19M | 99.10% | -336.35% | -332.08% |
| 2015 | $48.26M | $-43.02M | 96.07% | -81.74% | -89.15% |
| 2016 | $26.35M | $-55.14M | 89.76% | -184.45% | -209.25% |
| 2017 | $25.19M | $-65.78M | 93.24% | -227.95% | -261.18% |
| 2018 | $20.65M | $-101.25M | 97.72% | -456.20% | -490.25% |
| 2019 | $48.84M | $-108.90M | 91.60% | -203.66% | -222.99% |
| 2020 | $17.81M | $-182.81M | 90.59% | -981.12% | -1,026.35% |
| 2021 | $157.17M | $-184.06M | 95.38% | -113.08% | -117.11% |
| 2022 | $270.83M | $-247.12M | 97.57% | -54.81% | -91.24% |
| 2023 | $331.41M | $-226.54M | 98.59% | -31.29% | -68.36% |
| 2024 | $450.71M | $-88.88M | 97.23% | -0.56% | -19.72% |
| 2025 | $874.84M | $263.86M | 97.82% | 38.98% | 30.16% |